These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 15386266

  • 1. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, Pontillo A, Bonfanti C, Sarmientos P, Caruso A.
    Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
    [Abstract] [Full Text] [Related]

  • 2. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 3. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
    Iaria ML, Fiorentini S, Focà E, Zicari S, Giagulli C, Caccuri F, Francisci D, Di Perri G, Castelli F, Baldelli F, Caruso A.
    Vaccine; 2014 Feb 19; 32(9):1072-8. PubMed ID: 24456624
    [Abstract] [Full Text] [Related]

  • 4. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
    Fiorentini S, Marsico S, Becker PD, Iaria ML, Bruno R, Guzmán CA, Caruso A.
    Vaccine; 2008 Aug 26; 26(36):4758-65. PubMed ID: 18602957
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D, Bolesta E, Naito T, Gzyl J, Kaneko Y, Kozbor D.
    J Hum Virol; 2001 Aug 26; 4(6):306-16. PubMed ID: 12082397
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
    Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A.
    Cell Mol Biol (Noisy-le-grand); 1995 May 26; 41(3):401-7. PubMed ID: 7580834
    [Abstract] [Full Text] [Related]

  • 7. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K, Kaneko T, Yamakawa T, Tanaka S, Shigematsu T, Yamamoto A, Hamajima K, Nakajima K, Kawamoto S, Phanuphak P.
    J Mol Recognit; 1993 Sep 26; 6(3):101-9. PubMed ID: 8060667
    [Abstract] [Full Text] [Related]

  • 8. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM.
    AIDS; 1993 Oct 26; 7(10):1315-23. PubMed ID: 8267904
    [Abstract] [Full Text] [Related]

  • 9. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A.
    Pharmacol Ther; 2010 Dec 26; 128(3):433-44. PubMed ID: 20816696
    [Abstract] [Full Text] [Related]

  • 10. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.
    De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, Poiesi C, Popovic M, Grassi M, Garrafa E, Bozzo L, Lewis GK, Licenziati S, Gallo RC, Caruso A.
    Proc Natl Acad Sci U S A; 2002 Jul 23; 99(15):9972-7. PubMed ID: 12105273
    [Abstract] [Full Text] [Related]

  • 11. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
    Lottersberger J, Salvetti JL, Beltramini LM, Tonarelli G.
    Rev Argent Microbiol; 2004 Jul 23; 36(4):151-7. PubMed ID: 15786866
    [Abstract] [Full Text] [Related]

  • 12. HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens.
    Fiorentini S, Becker PD, Marini E, Marconi P, Avolio M, Tosti G, Link C, Manservigi R, Guzman CA, Caruso A.
    Viral Immunol; 2006 Jul 23; 19(2):177-88. PubMed ID: 16817760
    [Abstract] [Full Text] [Related]

  • 13. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
    de Goede AL, Boers PH, Dekker LJ, Osterhaus AD, Gruters RA, Rimmelzwaan GF.
    Vaccine; 2009 Sep 25; 27(42):5735-9. PubMed ID: 19647812
    [Abstract] [Full Text] [Related]

  • 14. cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication.
    Tewari D, Goldstein SL, Notkins AL, Zhou P.
    J Immunol; 1998 Sep 01; 161(5):2642-7. PubMed ID: 9725267
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E, Mathy N, Bråve A, Boberg A, Kjerrström A, van Wely C, Engström G, Johansson S, Aperia K, Eriksson LE, Benthin R, Ertl P, Heeney J, Hinkula J, Voss G, Wahren B.
    Vaccine; 2007 Mar 01; 25(11):2145-54. PubMed ID: 17254672
    [Abstract] [Full Text] [Related]

  • 16. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K, Xin KQ, Jounai N, Kojima Y, Tamura Y, Okada E, Kawamoto S, Okuda K, Klinman D, Okuda K.
    Vaccine; 2004 Sep 09; 22(27-28):3676-90. PubMed ID: 15315847
    [Abstract] [Full Text] [Related]

  • 17. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
    Harrer T, Harrer E, Barbosa P, Kaufmann F, Wagner R, Brüggemann S, Kalden JR, Feinberg M, Johnson RP, Buchbinder S, Walker BD.
    J Immunol; 1998 Nov 01; 161(9):4875-81. PubMed ID: 9794421
    [Abstract] [Full Text] [Related]

  • 18. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
    McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ.
    Virology; 2006 Jan 20; 344(2):363-77. PubMed ID: 16226782
    [Abstract] [Full Text] [Related]

  • 19. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
    Naylor PH, Sztein MB, Wada S, Maurer S, Holterman D, Kirkley JE, Naylor CW, Zook BC, Hitzelberg RA, Gibbs CJ.
    Int J Immunopharmacol; 1991 Jan 20; 13 Suppl 1():117-27. PubMed ID: 1823903
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R, Meyer D.
    Vaccine; 2005 Mar 18; 23(17-18):2164-7. PubMed ID: 15755588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.